Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
Australian Senate Committee issues recommendation on Gene Patenting Bill (Patent Docs)
EU: Paediatrics and transitional periods: a reader writes (The SPC Blog)
Italy: Generics can be sued in the courts of the pharmacies, says the Court of Turin (Kluwer Patent Blog)
US: Appealing premarket disputes in the Device Center: Reform is needed (FDA Law Blog)
US: Lawyer, physician, and bioethicist takes over the reins at FDA’s orphan drug shop (FDA Law Blog)
US: Are prenatals marketed as unapproved drugs exempt from FDA’s September 19 guidance? No (FDA Law Blog)
US: Landmark NORD report on orphan drugs authored by HP&M Director shows FDA flexibility in approval (FDA Law Blog)
Embeda (Morphine sulfate, Naltrexone hydrochloride) – US: Pfizer, Alpharma, King Pharma. file patent infringement suit against Watson following Para IV certification (Patent Docs)
Exelon (Rivastigmine) – UK: EWHC (Pat): Rivastigmine patent, SPC held invalid: Generics (UK) Ltd (t/a Mylan) v Novartis AG (The SPC Blog)
Nexavar (Sorafenib) – India: The absence of evidence in NATCO’s CL application for Nexavar (Spicy IP)
Targretin (Bexarotene) – US: Eisai file patent infringement complaint against Banner Pharmacaps in response to Para IV certification (Patent Docs)
Tavanic (Levofloxacin hemihydrate) – EU: TRIPS case heading for the ECJ has an SPC in the underlying dispute: Case C-414/11 Daiichi Sankyo Company Limited, Sanofi-Aventis Deutschland GmbH v DEMO Anonimos Viomikhaniki kai Emporiki Etairia Farmakon (The SPC Blog) (IPKat)